Sanofi Submits NDA for Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide
PARIS, Dec. 23, 2015 /PRNewswire-USNewswire/ -- Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin glargine 100 Units/mL... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 23, 2015 Category: Drugs & Pharmacology Source Type: news
FDA Approves Less Expensive Insulin Glargine (FREE)
By Kristin J. Kelley
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
The FDA has approved an insulin glargine injection (marketed as Basaglar) for treating type 1 (adult and pediatric patients) and … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 18, 2015 Category: Primary Care Source Type: news
Insulin Glargine Copycat (Basaglar) Okayed by FDAInsulin Glargine Copycat (Basaglar) Okayed by FDA
The agency approved the long-lasting human insulin analogue because it is a biological and clinical dead ringer of diabetes drug Lantus. FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 17, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
Basaglar Gets FDA Nod in Diabetes
(MedPage Today) -- Insulin glargine injection deemed "sufficiently similar" to Lantus (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 17, 2015 Category: Primary Care Source Type: news
FDA approves Lilly and Boehringer's Basaglar insulin glargine product to treat diabetes
The US Food and Drug Administration has granted approval for Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with diabetes. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - December 17, 2015 Category: Pharmaceuticals Source Type: news
FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes
The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 16, 2015 Category: American Health Source Type: news
FDA Approves Basaglar® (insulin glargine injection), a Long-Acting Insulin Treatment
• BASAGLAR is the first FDA-approved follow-on insulin glargine treatment • BASAGLAR will be available in the U.S. starting on December 15, 2016 (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - December 15, 2015 Category: Research Source Type: news
Basal insulin peglispro beats glargine for glycemic control
For patients with type 2 diabetes, basal insulin peglispro (BIL) provides better glycemic control than insulin glargine, with increased triglycerides, aminotransferases, and liver fat content, according to a study published online in the journal Diabetes Care.
Medical Xpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 1, 2015 Category: Endocrinology Source Type: news
Sanofi Settles Insulin Suit with Rivals Lilly, BI
Sanofi has settled a lawsuit over patents for Lantus SoloStar, its once-daily insulin in an injector-device, allowing partners Eli Lilly and Boehringer Ingelheim to sell their version in the U.S. starting December 2016. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 1, 2015 Category: Pharmaceuticals Source Type: news
Tresiba U200 delivers lower rates of hypoglycaemia
New data show that patients with type 2 diabetes receiving the U200 formulation of Tresiba experienced significantly lower rates of confirmed hypoglycaemia and significantly reduced mean fasting blood glucose compared to those receiving insulin glargine U100.
European Pharmaceutical Review (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 15, 2015 Category: Endocrinology Source Type: news
Lilly Insulin Tops Sanofi's Lantus in Trials; Liver Issue PersistsLilly Insulin Tops Sanofi's Lantus in Trials; Liver Issue Persists
A long-acting insulin being developed by Eli Lilly and Co demonstrated greater blood sugar reduction than Sanofi SA's top-selling Lantus in patients with type 2 diabetes, according to data from three Phase III trials presented on Saturday. Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 9, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Toujeo for the Treatment of Type 1 and Type 2 Diabetes
Toujeo (insulin glargine [rDNA origin]) is an insulin injection approved for the treatment of type 1 and type 2 diabetes to improve glycaemic control in adult patients. (Source: Drug Development Technology)
Source: Drug Development Technology - April 16, 2015 Category: Pharmaceuticals Source Type: news
Biocon gets approval for insulin Glargine in Mexico
Galactus by PiSA is the first insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012, it added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 9, 2015 Category: Pharmaceuticals Source Type: news
Toujeo (Insulin Glargine Injection for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 10, 2015 Category: Drugs & Pharmacology Source Type: news
EU Gives Green Light to Toujeo, a Better Insulin Glargine?EU Gives Green Light to Toujeo, a Better Insulin Glargine?
Sanofi's U-300, or ultralong-acting insulin glargine, Toujeo has been given a positive opinion by the CHMP of the European Medicines Agency. The product is designed to improve on Lantus. International Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 28, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
